Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo de revisión (ReviewArticle)

Brain JNK and metabolic disease.

  • Nogueiras, Rubén
  • Sabio, Guadalupe
Obesity, which has long since reached epidemic proportions worldwide, is associated with long-term stress to a variety of organs and results in diseases including type 2 diabetes. In the brain, overnutrition induces hypothalamic stress associated with the activation of several signalling pathways, together with central insulin and leptin resistance. This central action of nutrient overload appears very rapidly, suggesting that nutrition-induced hypothalamic stress is a major upstream initiator of obesity and associated diseases. The cellular response to nutrient overload includes the activation of the stress-activated c-Jun N-terminal kinases (JNKs) JNK1, JNK2 and JNK3, which are widely expressed in the brain. Here, we review recent findings on the regulation and effects of these kinases, with particular focus on the hypothalamus, a key brain region in the control of energy and glucose homeostasis. JNK1 blocks the hypothalamic-pituitary-thyroid axis, reducing energy expenditure and promoting obesity. Recently, opposing roles have been identified for JNK1 and JNK3 in hypothalamic agouti gene-related protein (AgRP) neurons: while JNK1 activation in AgRP neurons induces feeding and weight gain and impairs insulin and leptin signalling, JNK3 (also known as MAPK10) deletion in the same neuronal population produces very similar effects. The opposing roles of these kinases, and the unknown role of hypothalamic JNK2, reflect the complexity of JNK biology. Future studies should address the specific function of each kinase, not only in different neuronal subsets, but also in non-neuronal cells in the central nervous system. Decoding the puzzle of brain stress kinases will help to define the central stimuli and mechanisms implicated in the control of energy balance. Graphical abstract.
Repisalud
Publicación Artículo científico (JournalArticle)

Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function.

  • da Silva Lima, Natália
  • Fondevila, Marcos F
  • Nóvoa, Eva
  • Buqué, Xabier
  • Mercado-Gómez, Maria
  • Gallet, Sarah
  • González-Rellan, Maria J
  • Fernandez, Uxia
  • Loyens, Anne
  • Garcia-Vence, Maria
  • Chantada-Vazquez, Maria Del Pilar
  • Bravo, Susana-Belén
  • Marañon, Patricia
  • Senra, Ana
  • Escudero, Adriana
  • Leiva, Magdalena
  • Guallar, Diana
  • Fidalgo, Miguel
  • Gomes, Pedro
  • Claret, Marc
  • Sabio, Guadalupe
  • Varela-Rey, Marta
  • Delgado, Teresa C
  • Montero-Vallejo, Rocio
  • Ampuero, Javier
  • López, Miguel
  • Diéguez, Carlos
  • Herrero, Laura
  • Serra, Dolors
  • Schwaninger, Markus
  • Prevot, Vincent
  • Gallego-Duran, Rocio
  • Romero-Gomez, Manuel
  • Iruzubieta, Paula
  • Crespo, Javier
  • Martinez-Chantar, Maria L
  • Garcia-Monzon, Carmelo
  • Gonzalez-Rodriguez, Agueda
  • Aspichueta, Patricia
  • Nogueiras, Ruben
BACKGROUND & AIMS: Autophagy-related gene 3 (ATG3) is an enzyme mainly known for its actions in the LC3 lipidation process, which is essential for autophagy. Whether ATG3 plays a role in lipid metabolism or contributes to non-alcoholic fatty liver disease (NAFLD) remains unknown. METHODS: By performing proteomic analysis on livers from mice with genetic manipulation of hepatic p63, a regulator of fatty acid metabolism, we identified ATG3 as a new target downstream of p63. ATG3 was evaluated in liver samples from patients with NAFLD. Further, genetic manipulation of ATG3 was performed in human hepatocyte cell lines, primary hepatocytes and in the livers of mice. RESULTS: ATG3 expression is induced in the liver of animal models and patients with NAFLD (both steatosis and non-alcoholic steatohepatitis) compared with those without liver disease. Moreover, genetic knockdown of ATG3 in mice and human hepatocytes ameliorates p63- and diet-induced steatosis, while its overexpression increases the lipid load in hepatocytes. The inhibition of hepatic ATG3 improves fatty acid metabolism by reducing c-Jun N-terminal protein kinase 1 (JNK1), which increases sirtuin 1 (SIRT1), carnitine palmitoyltransferase 1a (CPT1a), and mitochondrial function. Hepatic knockdown of SIRT1 and CPT1a blunts the effects of ATG3 on mitochondrial activity. Unexpectedly, these effects are independent of an autophagic action. CONCLUSIONS: Collectively, these findings indicate that ATG3 is a novel protein implicated in the development of steatosis. LAY SUMMARY: We show that autophagy-related gene 3 (ATG3) contributes to the progression of non-alcoholic fatty liver disease in humans and mice. Hepatic knockdown of ATG3 ameliorates the development of NAFLD by stimulating mitochondrial function. Thus, ATG3 is an important factor implicated in steatosis.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Temperature modulates systemic and central actions of thyroid hormones on BAT thermogenesis

  • Rial Pensado, Eva
  • Rivas Limeres, Verónica
  • Grijota Martínez, Carmen
  • Rodríguez Díaz, Amanda
  • Capelli, Vallentina
  • Barca Mayo, Olga
  • Nogueiras Pozo, Rubén
  • Mittag, Jens
  • Diéguez González, Carlos
  • López Pérez, Miguel A.
Thyroid hormones (THs) play a major role regulating energy balance and brown adipose tissue (BAT) thermogenesis, as well as body temperature, as shown in hyperthyroid patients. However, the current landscape of preclinical thyroid hormone models is complex. For example, while rats become catabolic after TH administration, mice gain weight; so, these differences in species need to be analyzed in detail and specially whether temperature could be a factor. Here, we aimed to investigate the effect of environmental temperature on those actions. Rats were subcutaneously treated with L-thyroxine (T4) or stereotaxically within the ventromedial nucleus of the hypothalamus (VMH) with triiodothyronine (T3) and housed at 23°C, 4°C or 30°C; energy balance, BAT thermogenesis and AMP-activated protein kinase (AMPK) in the VMH were analyzed. Our data showed that the effect of both systemic T4 of central T3 on energy balance and BAT thermogenesis was dependent upon environmental temperature. This evidence is of interest in the design of experimental settings highlighting the species-specific metabolic actions of THs, and in understanding its physiological role in the adaptation to temperature.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Is LRP2 Involved in Leptin Transport over the Blood-Brain Barrier and Development of Obesity?

  • Sandin, Elvira S.
  • Folberth, Julica
  • Müller-Fielitz, Helge
  • Pietrzik, Claus Ulrich
  • Herold, Elisabeth
  • Willnow, Thomas
  • Pfluger, Paul
  • Nogueiras Pozo, Rubén
  • Prevot, Vincent
  • Krey, Thomas
  • Schwaninger, Markus
The mechanisms underlying the transport of leptin into the brain are still largely unclear. While the leptin receptor has been implicated in the transport process, recent evidence has suggested an additional role of LRP2 (megalin). To evaluate the function of LRP2 for leptin transport across the blood-brain barrier (BBB), we developed a novel leptin-luciferase fusion protein (pLG), which stimulated leptin signaling and was transported in an in vitro BBB model based on porcine endothelial cells. The LRP inhibitor RAP did not affect leptin transport, arguing against a role of LRP2. In line with this, the selective deletion of LRP2 in brain endothelial cells and epithelial cells of the choroid plexus did not influence bodyweight, body composition, food intake, or energy expenditure of mice. These findings suggest that LRP2 at the BBB is not involved in the transport of leptin into the brain, nor in the development of obesity as has previously been described
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function

  • Lima, Natália da Silva
  • Fondevila, Marcos F.
  • Nóvoa, Eva
  • Buqué, Xabier
  • Mercado-Gómez, María
  • Gallet, Sarah
  • González-Rellán, María Jesús
  • Fernández, Uxía
  • Loyens, Anne
  • García-Vence, María
  • Chantada-Vázquez, María del Pilar
  • Bravo, Susana Belén
  • Marañón, Patricia
  • Senra, Ana
  • Escudero, Adriana
  • Leiva, Magdalena
  • Guallar, Diana
  • Fidalgo, Miguel
  • Gomes, Pedro
  • Claret, Marc
  • Sabio, Guadalupe
  • Varela-Rey, Marta
  • Delgado, Teresa C.
  • Montero-Vallejo, Rocío
  • Ampuero, Javier
  • López, Miguel
  • Diéguez, Carlos
  • Herrero, Laura
  • Serra, Dolors
  • Schwaninger, Markus
  • Prevot, Vincent
  • Gallego-Durán, Rocío
  • Romero-Gómez, Manuel
  • Iruzubieta, Paula
  • Crespo, Javier
  • Martínez-Chantar, María Luz
  • García-Monzón, Carmelo
  • González-Rodríguez, Águeda
  • Aspichueta, Patricia
  • Nogueiras, Rubén
[Background & Aims] Autophagy-related gene 3 (ATG3) is an enzyme mainly known for its actions in the LC3 lipidation process, which is essential for autophagy. Whether ATG3 plays a role in lipid metabolism or contributes to non-alcoholic fatty liver disease (NAFLD) remains unknown., [Methods] By performing proteomic analysis on livers from mice with genetic manipulation of hepatic p63, a regulator of fatty acid metabolism, we identified ATG3 as a new target downstream of p63. ATG3 was evaluated in liver samples from patients with NAFLD. Further, genetic manipulation of ATG3 was performed in human hepatocyte cell lines, primary hepatocytes and in the livers of mice., [Results] ATG3 expression is induced in the liver of animal models and patients with NAFLD (both steatosis and non-alcoholic steatohepatitis) compared with those without liver disease. Moreover, genetic knockdown of ATG3 in mice and human hepatocytes ameliorates p63- and diet-induced steatosis, while its overexpression increases the lipid load in hepatocytes. The inhibition of hepatic ATG3 improves fatty acid metabolism by reducing c-Jun N-terminal protein kinase 1 (JNK1), which increases sirtuin 1 (SIRT1), carnitine palmitoyltransferase 1a (CPT1a), and mitochondrial function. Hepatic knockdown of SIRT1 and CPT1a blunts the effects of ATG3 on mitochondrial activity. Unexpectedly, these effects are independent of an autophagic action., [Conclusions] Collectively, these findings indicate that ATG3 is a novel protein implicated in the development of steatosis., This work has been supported by grants from FEDER/Ministerio de Ciencia, Innovación y Universidades-Agencia Estatal de Investigación (PA: RTI2018-095134-B-100; DS and LH: SAF2017-83813-C3-1-R; MLMC: RTC2019-007125-1; CD: BFU2017-87721; ML: RTI2018–101840-B-I00; GS; PID2019-104399RB-I00; RN: RTI2018-099413-B-I00 and RED2018-102379-T; MLMC: SAF2017-87301-R; TCD: RTI2018-096759-A-100), FEDER/Instituto de Salud Carlos III (AGR: PI19/00123), Xunta de Galicia (ML: 2016-PG068; RN: 2015-CP080 and 2016-PG057), Fundación BBVA (RN, GS and MLM), Proyectos Investigación en Salud (MLMC: DTS20/00138), Sistema Universitario Vasco (PA: IT971-16); Fundación Atresmedia (ML and RN), Fundación La Caixa (M.L., R.N. and M.C.), Gilead Sciences International Research Scholars Program in Liver Disease (MVR), Marató TV3 Foundation (DS: 201627), Government of Catalonia (DS: 2017SGR278) and European Foundation for the Study of Diabetes (RN and GS). This research also received funding from the European Community’s H2020 Framework Programme (ERC Synergy Grant-2019-WATCH- 810331, to RN, VP and MS). Centro de Investigación Biomédica en Red (CIBER) de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Hepáticas y Digestivas (CIBERehd) and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem). CIBERobn, CIBERehd and CIBERdem are initiatives of the Instituto de Salud Carlos III (ISCIII) of Spain which is supported by FEDER funds. We thank MINECO for the Severo Ochoa Excellence Accreditation to CIC bioGUNE (SEV-2016-0644)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neddylation of phosphoenolpyruvate carboxykinase 1 controls glucose metabolism

  • Gonzalez-Rellan, María J
  • Fernández, Uxía
  • Parracho, Tamara
  • Novoa, Eva
  • Fondevila, Marcos F
  • da Silva Lima, Natalia
  • Ramos, Lucía
  • Rodríguez, Amaia
  • Serrano-Maciá, Marina
  • Pérez-Mejías, Gonzalo
  • Chantada-Vazquez, Pilar
  • Riobello, Cristina
  • Veyrat-Durebex, Christelle
  • Tovar, Sulay
  • Coppari, Roberto
  • Woodhoo, Ashwin
  • Schwaninger, Markus
  • Prevot, Vincent
  • Delgado, Teresa C.
  • Lopez, Miguel
  • Díaz-Quintana, Antonio
  • Dieguez, Carlos
  • Guallar, Diana
  • Frühbeck, Gema
  • Díaz-Moreno, Irene
  • Bravo, Susana B
  • Martinez-Chantar, Maria L
  • Nogueiras, Ruben
Neddylation is a post-translational mechanism that adds a ubiquitin-like protein, namely neural precursor cell expressed developmentally downregulated protein 8 (NEDD8). Here, we show that neddylation in mouse liver is modulated by nutrient availability. Inhibition of neddylation in mouse liver reduces gluconeogenic capacity and the hyperglycemic actions of counter-regulatory hormones. Furthermore, people with type 2 diabetes display elevated hepatic neddylation levels. Mechanistically, fasting or caloric restriction of mice leads to neddylation of phosphoenolpyruvate carboxykinase 1 (PCK1) at three lysine residues-K278, K342, and K387. We find that mutating the three PCK1 lysines that are neddylated reduces their gluconeogenic activity rate. Molecular dynamics simulations show that neddylation of PCK1 could re-position two loops surrounding the catalytic center into an open configuration, rendering the catalytic center more accessible. Our study reveals that neddylation of PCK1 provides a finely tuned mechanism of controlling glucose metabolism by linking whole nutrient availability to metabolic homeostasis., This work was supported by grants from: FEDER/Ministerio de Ciencia, Innovación y Universidades-Agencia Estatal de Investigación (M.L.M.-C.: PID2020-117116RB-I00; C.D.: BFU2017-87721; M.L.: RTI2018-101840-B-I00; R.N.: PID2021-126096NB-I00 and RED2018-102379-T); Xunta de Galicia (R.N.: 2021-CP085 and 2020-PG0157); Fundación BBVA (to R.N.); Subprograma Retos Colaboración RTC2019-007125-1 (to M.L.M.-C.); Proyectos Investigación en Salud DTS20/00138 (to M.L.M.-C.); Proyectos Investigación en Salud (M.L.M.-C.: DTS20/00138); Fundación Atresmedia (to M.L. and R.N.); and Fundación La Caixa (to M.L., M.L.M.-C., and R.N.). This research also received funding from the European Community’s H2020 Framework Programme (ERC Synergy Grant-2019-WATCH- 810331, to R.N., V.P., and M.S.). The Centro de Investigación Biomédica en Red (CIBER) de Fisiopatología de la Obesidad y Nutrición (CIBERobn) and the Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Hepáticas y Digestivas (CIBERehd) are initiatives of the Instituto de Salud Carlos III (ISCIII) of Spain, which is supported by FEDER funds. We thank MINECO for the Severo Ochoa Excellence Accreditation bioGUNE (SEV-2016-0644) to CIC., Peer reviewed